Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for QKI drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | QKI Recombinant Protein (Full-Length & Isoform-Specific) High purity (>95%), Endotoxin Controlled. Sequence Verified. Theoretical MW confirmed by MS. |
View QKI Products |
| Gene Delivery | QKI Promise-ORF / Lentivirus Isoform-specific (QKI-5, QKI-6, QKI-7) full-length ORF for stable cell line construction. |
View QKI Products |
| Benchmark Ab | Anti-QKI Recombinant Antibody Recombinant positive control for immunoprecipitation, Western Blot, and IHC. |
View QKI Products |
| Validator | QKI siRNA Set Target-specific knockdown pool for functional validation in splicing assays. |
View QKI Products |
| Related Target A | PTBP1 Splicing regulator working in tandem or opposition to QKI in glioblastoma and neuronal lineage determination. |
View PTBP1 Products |
| Related Target B | MYRF Downstream transcription factor regulated by QKI-mediated splicing during oligodendrocyte myelination. |
View MYRF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform-Specific Cross-Reactivity (QKI-5 vs. QKI-6 vs. QKI-7) | Isoform-specific recombinant proteins and lentiviral vectors strictly sequence-verified. |
| RNA-Binding Domain (KH Domain) Conformational Stability | HEK293-expressed proteins preserving native post-translational modifications (methylation/phosphorylation). |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives in Splicing Modulation | Validated isoform-specific siRNA included for functional knockdown verification |
Live QKI R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for QKI therapeutics is intensifying, with major players shifting focus from traditional oncology targets to RNA-binding protein (RBP) modulation and alternative splicing control. As first-generation therapies targeting splicing machinery reach the clinic, the next wave of R&D is targeting QKI's dual role as a tumor suppressor in specific solid tumors and a driver of epithelial-mesenchymal transition (EMT) and drug resistance in chemotherapy-refractory cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule RBP Inhibitors | Academic Consortia, Biotech Startups | Glioblastoma, Non-Small Cell Lung Cancer (NSCLC) | RNA-binding inhibition assays (Requires high-purity, active-site verified QKI recombinant protein) |
| Gene Therapy / mRNA | Neurological Therapeutics Developers | Demyelinating Diseases, Schizophrenia | Stable expression verification (Requires QKI-5/6/7 Lentivirus for functional rescue assays) |
| Antisense Oligonucleotides (ASOs) | RNA-targeting Biopharma | Metastatic Colorectal Cancer, EMT-driven Tumors | Splicing correction assays (Requires sequence-verified QKI siRNA and isoform-specific detection tools) |